Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...